Abstract
The diagnostic accuracy of thyroid nodule (TN) evaluation remains a challenge, particularly in cases of indeterminate cytology. This study investigates whether biochemical markers—specifically thyroglobulin (TG), nitric oxide (NO), and calcitonin (CT)—measured in the washout fluid from fine-needle aspiration biopsies (FNAB) can serve as reliable predictors of malignancy. Our findings suggest that local levels of TG (TGw) and NO (NOw) in the nodule microenvironment are significantly more informative than systemic serum levels, offering a potential pathway to refine diagnostic precision for patients in the Bethesda III and IV categories.
Introduction
Thyroid nodules are a common clinical finding, yet only a small fraction (1–5%) are malignant. The current standard for diagnosis is ultrasound-guided Fine-Needle Aspiration Biopsy (FNAB), with results categorized by the Bethesda system. However, approximately 15–30% of these biopsies fall into the "indeterminate" categories (Bethesda III and IV), creating a diagnostic "gray zone." In these instances, clinicians face the dilemma of either recommending surgery for potentially benign nodules or adopting a "wait and see" approach that may delay treatment for cancer. This study explores the utility of measuring biochemical markers directly from the biopsy needle washout to provide objective data for risk stratification.
Methodology
A cross-sectional study was conducted involving 86 patients with thyroid nodules larger than 1 cm. Following standard FNAB, the biopsy needle was rinsed with 1 ml of physiological saline to collect "washout" fluid. Levels of NO, TG, and CT were measured in both the patient's serum and this washout fluid. These biochemical markers were then correlated with ultrasound findings (EU-TIRADS) and cytological results (Bethesda scale). For the subset of 20 patients who underwent surgical intervention, markers were compared against the definitive histological diagnosis.
Key Results
The study revealed that local biochemical markers in the washout fluid are far more predictive of malignancy than their systemic counterparts.
Washout thyroglobulin (TGw) demonstrated a significant positive correlation with the Bethesda classification (ρ = 0.250, p < 0.05). In patients with surgically confirmed malignancy, TGw levels were markedly higher, suggesting its potential as a gradient for malignant risk.
Similarly, washout nitric oxide (NOw) levels correlated strongly with suspicious ultrasound features (EU-TIRADS), even though they did not directly correlate with cytological cell types. This suggests that NO may play a role in the morphological changes associated with suspicious nodules, such as increased vascularity.
Crucially, serum levels of NO, TG, and CT showed no significant correlation with cytological findings, reinforcing the conclusion that systemic blood tests are insufficient for characterizing individual thyroid nodules.
Discussion and Clinical Implications
The concentration of diagnostic power within the nodule's microenvironment is a key takeaway. By leveraging the washout fluid—a byproduct of the existing biopsy procedure—clinicians can gain additional diagnostic insights without further patient trauma. The ability of TGw to risk-stratify indeterminate cases could significantly reduce unnecessary surgeries.
However, the study is limited by its sample size (n=86) and the lack of a global standard for washout volumes. Future research should focus on larger, multi-center trials to establish clinical "cut-off" values and explore the integration of these biochemical markers with molecular testing to create a comprehensive diagnostic panel.
Conclusion
TGw and NOw represent promising adjuncts to traditional FNAB and ultrasound. Their inclusion in diagnostic protocols could help clear the ambiguity of indeterminate thyroid biopsies, leading to more personalized and effective patient management.
Summary updated